Transgenomics (TBIO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transgenomics (TBIO)

TBIO 0.0500

0.0%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: jmartin164	3/15/2013 6:17:08 PM
	of 17

TBIO $2.00 Price Target Transgenomic Rated “Outperform” by Zacks Mar 15th, 2013 5PM Transgenomic (NASDAQ: TBIO)‘s stock had its “outperform” rating reaffirmed by Zacks in a report released on Friday. They currently have a $2.00 target price on the stock. Zacks‘ analyst wrote, “New product launches will help drive revenue in the clinical lab business. C-GAAP (Plavix response) test could be a winner for TBIO. ScoliScore looks like a needle-mover too. TBIO recently added headcount to support a bigger roll-out of both tests and expects this to really take hold starting in 2013. Early indications also suggest TBIO’s novel, ultra-sensitive ICE COLD PCR testing technology is garnering significant interest from pharma companies and medical institutions. Key to longer-term revenue growth will be to gain further traction in the pharmacogenomics segment, revenue from which has been somewhat disappointing but will hopefully p/u in 2013 with increased activity from key customers. We are maintaining our Outperform rating. Our per share price target is $2.00. “ Shares of Transgenomic (NASDAQ: TBIO) remained flat at $0.44 during during mid-day trading trading on Friday. Transgenomic has a 52 week low of $0.39 and a 52 week high of $1.34. The stock’s 50-day moving average is currently $0.47. The company’s market cap is $31.5 million. Transgenomic (NASDAQ: TBIO) last released its earnings data on Wednesday, March 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). On average, analysts predict that Transgenomic will post $-0.10 earnings per share for the current fiscal year. Transgenomic, Inc. is a biotechnology company operates in two segments: Clinical Laboratories, Pharmacogenomics Services and Diagnostic Tools. To view Zacks’ full report, visit www.zacks.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext